Get started
Author

Esther Duperchy

Observed names: Duperchy, Esther, E. Duperchy
OpenAlex ID: A5034952120
Long-Term Experimental Evolution inEscherichia coli.IX. Characterization of Insertion Sequence-Mediated Mutations and Rearrangements
2000 · Dominique Schneider, Esther Duperchy, et al. · Genetics · 138
Design of Next Generation Polymyxins with Lower Toxicity: The Discovery of SPR206
2019 · Pamela Brown, Elizabeth Abbott, et al. · ACS Infectious Diseases · 87
Genomic comparisons among Escherichia coli strains B, K-12, and O157:H7 using IS elements as molecular markers
2002 · Dominique Schneider, Esther Duperchy, et al. · BMC Microbiology · 65
PDF
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response
2024 · Pablo C Okhuysen, Mayur S Ramesh, et al. · Clinical Infectious Diseases · 39
PDF
Influence of Lipophilicity on the Antibacterial Activity of Polymyxin Derivatives and on Their Ability to Act as Potentiators of Rifampicin
2021 · Pamela Brown, Omar Abdulle, et al. · ACS Infectious Diseases · 31
A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020–2021
2023 · D. R. Snydman, L. A. McDermott, et al. · Antimicrobial Agents and Chemotherapy · 16
The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic
2023 · Clive S. Mason, Tim Avis, et al. · Antimicrobial Agents and Chemotherapy · 14
PDF
Direct modifications of the cyclic peptide Polymyxin B leading to analogues with enhanced in vitro antibacterial activity
2020 · Pamela Brown, Omar Abdulle, et al. · Bioorganic & Medicinal Chemistry Letters · 13
730. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ridinilazole Compared with Vancomycin for the Treatment of Clostridioides difficile Infection
2022 · Pablo C Okhuysen, Mayur Ramesh, et al. · Open Forum Infectious Diseases · 6
PDF
1669. A US Based National Surveillance Study for the Susceptibility and Epidemiology of Clostridioides difficile Associated Diarrheal Isolates with Special Reference to Ridinilazole: 2020-2021
2022 · Laura A McDermott, Cheleste M Thorpe, et al. · Open Forum Infectious Diseases · 3
PDF
Early prediction of vasopressor initiation in ICU sepsis patients using an interpretable EHR-based ML model
2025 · Lucas Duval, Antoine Villié, et al. · BMC Medical Informatics and Decision Making · 2
PDF
1052. Characterisation of the DNA binding properties of ridinilazole, a selective antibiotic currently in phase III trials for the treatment of Clostridioides difficile
2021 · Clive Mason, Tim Avis, et al. · Open Forum Infectious Diseases · 2
A simple and rapid procedure to obtain aseptic larvae of the Colorado potato beetle, Leptinotarsa decemlineata, for molecular investigations
2003 · Esther Duperchy, Gisbert Zimmermann · Journal of Invertebrate Pathology · 2
CCDC 1969362: Experimental Crystal Structure Determination
2019 · Brown, Pamela, Abbott, Elizabeth, et al. · The Cambridge Structural Database
1361. Pharmacokinetics and Safety of Ridinilazole (RDZ), a Potential New Therapy for Clostridium difficile Infection (CDI): From Animal Models to Patients
2018 · Esther Duperchy, Sumita Chowdhury, et al. · Open Forum Infectious Diseases
1369. Combined Analysis of the In Vitro Activity of Ridinilazole (RDZ) Against More Than 500 Clostridium difficile (CD) Clinical Isolates and Impact of RDZ on Cell Morphology
2018 · Esther Duperchy, Eugénie Bassères, et al. · Open Forum Infectious Diseases
Identification of up-regulated genes of the hyphomycete, Beauveria bassiana, during infection of Leptinotarsa decemlineata
2003 · Duperchy, Esther · heiDOK (Heidelberg University)
PDF
Works count: 17
Citation count: 418
H-index: 8
I10-index: 8
Year
Topic
Type